4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO David Kirn Sells 12,930 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO David Kirn sold 12,930 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $24,466,434.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

4D Molecular Therapeutics Stock Down 4.5 %

Shares of 4D Molecular Therapeutics stock traded down $0.99 during trading hours on Wednesday, hitting $21.01. 832,424 shares of the company’s stock traded hands, compared to its average volume of 863,338. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $36.25. The stock has a 50 day simple moving average of $24.67 and a 200-day simple moving average of $24.67.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.07. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.44 million. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. As a group, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently bought and sold shares of FDMT. Trexquant Investment LP acquired a new position in 4D Molecular Therapeutics in the third quarter worth about $566,000. RA Capital Management L.P. boosted its stake in 4D Molecular Therapeutics by 35.6% in the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock valued at $52,998,000 after acquiring an additional 1,093,680 shares during the period. Wellington Management Group LLP boosted its stake in 4D Molecular Therapeutics by 2.2% in the third quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock valued at $2,199,000 after acquiring an additional 3,638 shares during the period. SG Americas Securities LLC boosted its stake in 4D Molecular Therapeutics by 119.5% in the fourth quarter. SG Americas Securities LLC now owns 26,899 shares of the company’s stock valued at $545,000 after acquiring an additional 14,645 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in 4D Molecular Therapeutics by 359.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after acquiring an additional 3,873 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. BMO Capital Markets reduced their price target on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st. Jefferies Financial Group increased their target price on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, June 7th. Barclays initiated coverage on 4D Molecular Therapeutics in a research report on Monday, April 15th. They issued an “overweight” rating on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Buy” and an average target price of $45.63.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.